Gregory A. Stoloff
Central Point
London, ENG, United Kingdom
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Novel Lipid Formulation Increases Absorption of Oral Cannabidiol (CBD).
Journal: Pharmaceutics
Published: November 04, 2024
Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial.
Journal: EBioMedicine
Published: August 13, 2022
FLU-v, a Broad-Spectrum Influenza Vaccine, Induces Cross-Reactive Cellular Immune Responses in Humans Measured by Dual IFN-γ and Granzyme B ELISpot Assay.
Journal: Vaccines
Published: June 22, 2022
Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults: A Randomized Clinical Trial.
Journal: Annals of internal medicine
Published: March 10, 2020
Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial.
Journal: Lancet (London, England)
Published: February 29, 2020
Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
Journal: BMC infectious diseases
Published: November 30, 2016
A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.
Journal: Clinical and vaccine immunology : CVI
Published: February 23, 2015
Meta-Analysis and Potential Role of Preexisting Heterosubtypic Cellular Immunity Based on Variations in Disease Severity Outcomes for Influenza Live Viral Challenges in Humans.
Journal: Clinical and vaccine immunology : CVI
Published: February 23, 2015
Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial.
Journal: Vaccine
Published: June 18, 2013
Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation.
Journal: Virology journal
Published: November 16, 2012
Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial.
Journal: Vaccine
Published: February 02, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026